Page 5 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers

Learning Objectives

Review and discuss the Canadian GU Research Consortium (GURC)

algorithm for advanced urothelial carcinoma, as well as detail on some
of the practice guidance recommendations

Discuss optimal timing of biomarker testing, i.e. for FGFR alterations and

PD-L1 expression, to provide guidance on how to incorporate new
treatment options, and the associated diagnostic testing, into clinical

practice (referencing the new management algorithm)

Review how to safely use FGFR inhibitors